ES2552512T3 - Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana - Google Patents

Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana Download PDF

Info

Publication number
ES2552512T3
ES2552512T3 ES12702946.0T ES12702946T ES2552512T3 ES 2552512 T3 ES2552512 T3 ES 2552512T3 ES 12702946 T ES12702946 T ES 12702946T ES 2552512 T3 ES2552512 T3 ES 2552512T3
Authority
ES
Spain
Prior art keywords
alkyl
group
formula
substituted
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12702946.0T
Other languages
English (en)
Spanish (es)
Inventor
Alicia Regueiro-Ren
Jacob Swidorski
Sing-Yuen Sit
Yan Chen
Jie Chen
Nicholas A. Meanwell
Zheng Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2552512T3 publication Critical patent/ES2552512T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES12702946.0T 2011-01-31 2012-01-27 Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana Active ES2552512T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161437870P 2011-01-31 2011-01-31
US201161437870P 2011-01-31
PCT/US2012/022847 WO2012106188A1 (en) 2011-01-31 2012-01-27 C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors

Publications (1)

Publication Number Publication Date
ES2552512T3 true ES2552512T3 (es) 2015-11-30

Family

ID=45567146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12702946.0T Active ES2552512T3 (es) 2011-01-31 2012-01-27 Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana

Country Status (19)

Country Link
US (1) US8748415B2 (enExample)
EP (1) EP2670764B1 (enExample)
JP (1) JP6000283B2 (enExample)
CN (1) CN103339141B (enExample)
BR (1) BR112014010105A2 (enExample)
CA (1) CA2826257A1 (enExample)
CY (1) CY1116989T1 (enExample)
DK (1) DK2670764T3 (enExample)
EA (1) EA023578B1 (enExample)
ES (1) ES2552512T3 (enExample)
HR (1) HRP20151212T1 (enExample)
HU (1) HUE026371T2 (enExample)
MX (1) MX2013008359A (enExample)
PL (1) PL2670764T3 (enExample)
PT (1) PT2670764E (enExample)
RS (1) RS54352B1 (enExample)
SI (1) SI2670764T1 (enExample)
SM (1) SMT201500303B (enExample)
WO (1) WO2012106188A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014002936A (es) 2011-09-21 2014-04-25 Bristol Myers Squibb Co Nuevos derivados de acido betulinico con actividad antiviral.
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
RU2516952C1 (ru) * 2012-11-09 2014-05-20 Леонид Леонидович Клопотенко Фармацевтическая композиция, содержащая инкапсулированную тритерпеновую кислоту или ее производные
RU2519133C1 (ru) * 2012-11-09 2014-06-10 Леонид Леонидович Клопотенко Мазь, содержащая инкапсулированную тритерпеновую кислоту или ее производные
CN103214543B (zh) * 2012-12-25 2015-09-02 中国人民解放军海军医学研究所 新山楂酸衍生物、其制备方法及其在抗肿瘤药物中的应用
US20140221361A1 (en) * 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
CN105102468A (zh) * 2013-02-25 2015-11-25 百时美施贵宝公司 用于治疗hiv的c-3烷基和烯基修饰的桦木酸衍生物
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
BR112017009853A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, uso de uma quantidade melhoradora de hiv de um composto
KR20170092581A (ko) 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 C17-아릴 치환된 베툴린산 유사체
WO2016168447A1 (en) * 2015-04-14 2016-10-20 VIIV HEALTHCARE (No.4) LIMITED Methods of producing an hiv maturation inhibitor
KR20180028535A (ko) * 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
JP2019502728A (ja) 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190135857A1 (en) * 2016-06-30 2019-05-09 Viiv Healthcare Uk (No. 5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2019055119A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION
WO2019055280A1 (en) 2017-09-13 2019-03-21 Emmyon, Inc. DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN
MX2020002884A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composición neuroprotectora mejorada para tratar afecciones neurológicas.
EP3784349B1 (en) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
US10343997B1 (en) 2018-12-04 2019-07-09 King Saud University Ursolic acid derivatives
RU2020130238A (ru) 2020-03-31 2022-03-14 Феникс Байотекнолоджи, Инк. Способ и композиции для лечения коронавирусной инфекции
EP4009981B1 (en) 2020-03-31 2023-08-16 Phoenix Biotechnology, Inc. Method and compositions for treating coronavirus infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN101142227A (zh) * 2004-11-12 2008-03-12 帕纳克斯医药公司 新颖的桦木醇衍生物、其制备和其用途
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
ES2548905T3 (es) * 2010-06-04 2015-10-21 Bristol-Myers Squibb Company Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
EP2576585B8 (en) * 2010-06-04 2016-12-21 VIIV Healthcare UK (No.5) Limited Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity

Also Published As

Publication number Publication date
DK2670764T3 (en) 2015-12-07
EP2670764A1 (en) 2013-12-11
HUE026371T2 (en) 2016-05-30
JP6000283B2 (ja) 2016-09-28
EP2670764B1 (en) 2015-09-02
SI2670764T1 (sl) 2016-03-31
EA201391098A1 (ru) 2013-12-30
WO2012106188A1 (en) 2012-08-09
PL2670764T3 (pl) 2016-02-29
CA2826257A1 (en) 2012-08-09
EA023578B1 (ru) 2016-06-30
PT2670764E (pt) 2015-11-20
US20130029954A1 (en) 2013-01-31
CY1116989T1 (el) 2017-04-05
CN103339141B (zh) 2016-08-24
CN103339141A (zh) 2013-10-02
JP2014507422A (ja) 2014-03-27
HRP20151212T1 (hr) 2015-12-04
SMT201500303B (it) 2016-01-08
US8748415B2 (en) 2014-06-10
MX2013008359A (es) 2013-08-27
RS54352B1 (sr) 2016-02-29
BR112014010105A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
ES2552512T3 (es) Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana
CL2022001478A1 (es) Agentes de iarn para infección causada por el virus de la hepatitis b. (divisional 201900278)
CR20240238A (es) Compuestos de carbamoyl piridona tricíclicos con puente y su uso farmacéutico (divisional 2021-0486)
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
CL2021001288A1 (es) Heterociclos funcionalizados como agentes antivirales
IL274901B2 (en) Substituted nucleosides, nucleotides and analogs thereof
CR20220109A (es) Profármacos antivirales y formulaciones de los mismos
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
NI201200139A (es) Compuestos de sililo tricíclicos fusionados y métodos de uso de los mismos para el tratamiento de enfermedades virales.
AR094876A1 (es) Derivados de ácido betulínico modificados con alquilo c-3 y alquenilo
CY1117113T1 (el) Αναστολεις πρωτεασης σερινης hcv λαμβανομενοι απο μακροκυκλικη προλινη
CO6361922A2 (es) Inhibidores del virus de la hepatitis c
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
NZ612159A (en) Macrocyclic inhibitors of flaviviridae viruses
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
JP2014507422A5 (enExample)
AR081691A1 (es) Derivados de tiofeno, metodos para su preparacion y su uso en el tratamiento o la prevencion de infecciones por flavivirus
AR081638A1 (es) Amidas c-28 de derivados del acido betulinico c-3 modificados como inhibidores de la maduracion del vih
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
NZ599133A (en) Hcv protease inhibitors
DOP2013000238A (es) Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EA202090514A1 (ru) Противовирусное средство против гепатита в
EA201200890A1 (ru) Комбинированная терапия hcv
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
CO2021011295A2 (es) Derivados de pirimidona de anillo fusionado para uso en el tratamiento de infección por vhb o enfermedades inducidas por vhb